Oticon president satisfied with FDA approval: "A huge milestone"
An approval from the US FDA for Oticon Medical's cochlear implant system Neuro can help the Danish company kick down the door to the US market for several products. The US approval might also pave the way for the products to become accessible outside the US, President Jes Olsen states.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Thursday is a happy day for Danish company Demant's bone-anchored division Oticon Medical, which has received approval for the company's cochlear implant system Neuro by the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Oticon Medical gets FDA approval for cochlear implant
For subscribers
Analyst: Demant's Oticon More generates strong VA figures
For subscribers
Demant won major market shares at VA in May
For subscribers
